MANAGEMENT OF CHRONIC IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA WITH SPLENECTOMY
Keywords:
chronic idiopathic thrombotic thrombocytopenic purpura, immunotherapy, splenectomyAbstract
Background. Treatment of thrombotic thrombocytopenic purpura (TTP) with plasma exchange (PE) has reduced mortality rates from 90% in untreated patients to less than 20%. Despite primary effective PE, relapses occur in up to 40% of patients. Beside PE, second line treatment options are corticosteroids, vincristine, defibrotide, prostacycline. We describe two patients with relapsing TTP treated successfully with splenectomy.
Patients and methods. Case 1. A 20–year female was diagnosed in October 2000 with idiopathic chronic relapsing TTP. First episode of PE plus methylprednisolone treatment led to complet remission. Subsequent relapses occured 3, 6 and 8 months after first TTP episode. Every relaps was effectivelly treated with PE and methylprednisolone. Because of more and more frequent TTP relapses laparoscopic splenectomy was performed. Currently, 7 months after splenectomy she is in complet TTP remission.
Case 2. A 18–year female, was diagnosed in January 1997 with idiopathic TTP. After PE and methylprednisolone complete remission was established. Relaps occured after nearly three years. Later on, TTP got chronic course with neurological clinical symptoms and plateled drops as soon as PE treatment was withdrawn. Besides PE and methylprednisolone she received also defibrotide. Because of chronic, PE dependant TTP, laparoscopic splenectomy was performed. Today, 15 months after splenectomy she is in complete TTP remission.
Conclusions. In idiopathic relapsing and chronic TTP, PE treatment only is usually not sufficient for durable remission. Second line TTP treatment drugs have limited efficacy. Based on our experience in patients with relapsing and/or chronic TTP, laparoscopic splenectomy should be considered as a first treatment option, especialy in junger patients.
Downloads
References
Gerritsen HE, Robled R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor – cleaving protease. Blood 2001; 98: 1654– 61.
Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor – cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662–6.
Rubia J, Lopez A, Arriga F et al. Response to plasma exchange and steroids as combined therapy for patients with thrombotic thrombocytopenic purpura. Acta Haematol 1999; 102: 12–6.
Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56: 191–207.
Allan DS, Kovacs MJ, Clark WF. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematol 2001; 86: 844–50.
Bell WR. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relaps: frequency, pathogenesis, and meaning. Semin Hematol 1997; 34: 134–9.
Lara PN Jr., Coe TL, Zhou H, Fernando L, Holland PV, Wun T. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura – hemolytic uremic syndrome. Am J Med 1999; 107: 573–9.
George JN. How I treat patients with thrombotic thrombocytopenic purpura – hemolytic uremic syndrome. Blood 2000; 96: 1223–8.
Hayward CPM, Sutton DMC, Carter WH Jr et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura – hemolytic uremic syndrome. Arch Inter Med. 1994; 154: 982–7.
Mant MJ, Turner AR, Ritchie BC, Larratt LM. Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency. Amer J of Hematol 1999; 62: 56–7.
Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura. Report of 16 cases and review of the literature. Medicine 1966; 45: 139–59.
Downloads
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
